logo
ScreenersREIT EarningsREIT SectorsIndustriesMarketplace
Logo

SciSparc Ltd.

SPRC

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement wā€¦ read more

Healthcare

Biotechnology

4 years

USD

Price

per share adjusted in USD

$2.75

Price

+3.00%

$0.08

$2.67

Previous Close

$2.60

Open

Premium

52w Discount
Market Cap

$1.418m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-786.7%

EBITDA Margin

-609.9%

Net Profit Margin

-623.6%

Free Cash Flow Margin
Revenue

$4.185m

+45.4%

1y CAGR

+61.7%

3y CAGR

+69.9%

5y CAGR
Earnings

-$11.406m

-122.7%

1y CAGR

-55.0%

3y CAGR

-57.6%

5y CAGR
EPS

-$81.55

-13.0%

1y CAGR

+23.2%

3y CAGR

+17.4%

5y CAGR
Book Value

$8.939m

$10.347m

Assets

$1.408m

Liabilities

$46k

Debt
Debt to Assets

0.4%

-

Debt to EBITDA
Free Cash Flow

-$10.991m

-86.7%

1y CAGR

-61.2%

3y CAGR

-50.5%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.